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Abstract
We evaluated 7 C. muridarum ORFs for their ability to induce protection against chlamydial infection in a mouse intravaginal
infection model. These antigens, although encoded in C. muridarum genome, are transcriptionally regulated by a cryptic
plasmid that is known to contribute to C. muridarum pathogenesis. Of the 7 plasmid-regulated ORFs, the chlamydial
glycogen phosphorylase or GlgP, when delivered into mice intramuscularly, induced the most pronounced protective
immunity against C. muridarum intravaginal infection. The GlgP-immunized mice displayed a significant reduction in vaginal
shedding of live organisms on day 14 after infection. The protection correlated well with a robust C. muridarum-specific
antibody and a Th1-dominant T cell responses, which significantly reduced the severity but not overall incidence of
hydrosalpinx. The GlgP-induced partial protection against upper genital tract pathology suggests that GlgP may be
considered a component for a multi-subunit vaccine. These results have demonstrated that intramuscular immunization of
mice with purified proteins can be used to identify vaccine antigens for preventing intravaginal infection with C. trachomatis
in humans.
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Introduction
Urogenital tract infection with Chlamydia trachomatis is a leading
cause of sexually transmitted bacterial infections [1,2,3]. Although
antibiotics are effective in treating chlamydial infection, due to the
lack of obvious symptoms, many infected individuals don’t seek
treatment, potentially leading to complications characterized with
inflammatory pathologies in the upper genital tract, including
pelvic inflammatory diseases, ectopic pregnancy and infertility
[1,4,5]. Obviously, a most effective means to prevent C. trachomatis-
induced complications is vaccination. However, there is still no
licensed C. trachomatis vaccine [6]. Immunization with formalin-
fixed whole C. trachomatis elementary body (EB) organisms not only
failed to induce long lasting protective immunity against trachoma
but also exacerbated ocular pathologies when some immunized
children were exposed to natural infection [7]. These observations
suggest that the formalin-fixed EB organisms may not only lack
protective antigens or contain protective antigens in incorrect
conformation but also carry pathogenic antigens. It is now known
that many chlamydia-secreted proteins may not be retained in the
EB organisms in any significant amounts [8,9,10,11]. It has also
been shown that the major outer membrane protein (MOMP) in
its native conformation is more powerful than non-native MOMP
in inducing protective immunity against chlamydial challenge
infection [12,13,14]. More importantly, extensive immunological
characterizations of chlamydial infection in animal models have
demonstrated that chlamydial antigen-specific immune responses
mediated by IFNg and dominated by Th1 T cells are essential for
protection against chlamydial infection [6,15,16], Thus, it may be
possible to induce protective immunity using the chlamydial
antigens if prepared and delivered appropriately.
The precise pathogenic mechanisms of C. trachomatis-induced
diseases remain unclear although both intracellular replication of
C. trachomatis organisms and host responses to C. trachomatis
antigens may significantly contribute to inflammatory pathologies
during C. trachomatis infection [17,18,19,20]. C. muridarum organ-
isms deficient in a cryptic plasmid failed to induce pathologies in
the upper genital tract while the wild type organisms were fully
capable of doing so [20,21]. Although C. muridarum organisms
cause no known human diseases, the organisms have been
extensively used to study immunobiology and search for vaccine
antigens of C. trachomatis [6,15,16,19,20,22,23]. Extensive immu-
nological studies, largely based on a C. muridarum intravaginal
infection mouse model, have revealed that a Th1-dominant cell-
mediated immunity is required for protection against Chlamydia
urogenital tract infection [6,15,16]. The plasmid-free C. trachomatis
organisms also displayed a reduced pathogenicity in mice [24].
The cryptic plasmid not only encodes 8 open reading frames
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ORFs [25]. It has been hypothesized that the plasmid-encoded
and/or -regulated ORFs may contribute to chlamydial pathogen-
esis.
In the current study, we used a C. muridarum intravaginal
infection mouse model to identify chlamydial antigens that can
induce protective immunity against chlamydial intravaginal
infection. We focused on chlamydial plasmid-regulated ORFs in
the current study because plasmid-encoded and/or regulated
genes have been proposed to play important roles in chlamydial
pathogenesis [21,25]. Among the 22 plasmid-regulated gene
products, 7 C. trachomatis proteins were significantly recognized
by C. trachomatis-infected women [26]. Since our long-term goal is
to develop a vaccine for humans, we compared the protection
efficacy of these 7 antigens using their orthologs from C. muridarum
in the mouse model. We found that the chlamydial glycogen
phosphorylase (GlgP), when delivered into mice intramuscularly,
induced the most pronounced protective immunity that partially
protected mice from chlamydial live organism infection and the
infection-induced upper genital tract pathology. The partial
protection further correlated with robust C. muridarum-specific
antibody and Th1-dominant T cell responses.
Results
1. Immunization with glycogen phosphorylase
significantly reduced live organism shedding following
an intravaginal infection
The chlamydial plasmid is known to transcriptionally regulate at
least 22 chlamydial chromosomal genes [25]. We screened 7 of the
plasmid-regulated gene products in a mouse intravaginal infection
model for induction of protective immunity (Fig. 1). The 7 proteins
include 3 hypothetical proteins with no known function (HP;
ORFs TC0075, TC0285 & TC0419), 3 glycogen metabolism
enzymes [glycogen synthase (GlgA, TC0181), glycogen branching
enzyme (GlgB, TC0257) & glycogen phosphorylase (GlgP,
TC0519)] and one acyltransferase (1-acyl-sn-glycerol-3-phosphate
acyltransferase or AGPAT, TC0156). The initial screening
experiment included 5 mice in each group. Despite the small
group size, the positive control group immunized with C. muridarum
live organisms (MoPn EBs) completely cleared infection on day 14
(p,0.01 when IFUs were compared, panel A; p,0.05 when the
number of mice with positive shedding was compared, panel B).
More importantly, the mouse groups immunized with the
hypothetical proteins TC0075 or TC0419 or glycogen phosphor-
ylase (GlgP) also displayed statistically significant reduction in
shedding of live organisms on day 14 post infection. However,
after correcting for multiple group comparisons, the p value only
from the GlgP-immunized group remained statistically significant.
2. GlgP-immunized mice displayed significantly less
severe hydrosalpinx
We also monitored the pathologies in the upper genital tract
tissues of the mice described above. The entire urogenital tracts
were visually inspected for both the presence of hydrosalpinx and
severity of hydrosalpinx based on the size of swollen oviducts
relative to the size of ovary on the same side as described
previously [19,20,27]. The overall incidences of hydrosalpinx were
similar between the GlgP-immunized and GST control groups
although the EB immunization group developed significantly
lower rates of hydrosalpinx (Fig. 2 panels A & B). Importantly,
when the severity of hydrosalpinx was compared, the GlgP-
immunized group developed significantly less severe hydrosalpinx
comparing to the GST control group (Fig. 2C). This reduced
severity of hydrosalpinx in the GlgP-immunized group correlated
well with reduced inflammatory infiltration examined under
microscope (data not shown). The GlgP-induced protection was
reproduced when more than 15 mice per group were used (Fig. 3).
Thus, GlgP immunization not only decreased the live organism
shedding from the lower genital tract but also reduced pathologies
in the upper genital tract following a challenge infection with C.
muridarum organisms.
3. Immunization with GlgP induced C. muridarum-specific
immune responses with a minimal cross-reactivity with
host GlgP
The immune responses induced by GlgP immunization were
monitored prior to C. muridarum challenge infection. Antibodies
from GlgP- and EB- but not GST-immunized groups labeled C.
muridarum inclusions in the infected HeLa cells (Fig. 4A). This
immunolabeling was specific since the antibody reactivities were
blocked by pre-absorption with specific antigens. The antibodies
from the GlgP-immunized mice also reacted with purified C.
muridarum EB organisms coated on the ELISA plate although the
titer was not as high as that from the EB-immunized group
(Fig. 4B). When the C. muridarum-specific antibodies were analyzed
for isotypes, both EB- and GlgP-immunized mice developed high
levels of IgG2a than IgG1 (Fig. 4C), indicating that both groups of
mice developed a Th1 dominant T cell response. Indeed,
splenocytes from both GlgP- and EB-immunized mice produced
high levels of the Th1 cytokine IFNg upon in vitro restimulation
with either EB or GlgP antigens (Fig. 5). GlgP is a highly conserved
phosphorylase and the chlamydial GlgP share ,50% amino acid
identity with GlgPs from mice (NP_722476 from brain,
NP_035354 from muscle or NP_573461 from liver) or human
(AAC18079) (http://www.ncbi.nlm.nih.gov/blast). We then tested
whether antibodies produced in mice immunized with chlamydial
GlgP could cross-react with mouse GlgP (Fig. 6). Surprisingly,
despite the high level of amino acid sequence homology, the anti-
chlamydial GlgP antibodies did not recognize GlgP from mouse
liver, brain or muscle tissues although under the same condition,
the chlamydial GlgP was significantly recognized. As a control, a
commercial rabbit anti-mouse GlgP antibody recognized both
mouse and chlamydial GlgP.
Discussion
To search for chlamydial vaccine candidate antigens, we used a
C. muridarum intravaginal infection mouse model to evaluate the
immunogenicity of and the ability to induce protective immunity
by C. muridarum antigens. The C. muridarum antigens were selected
when their counterparts in C. trachomatis were significantly
recognized by antibodies from women urogenitally infected with
C. trachomatis [26,27]. Since plasmid-free chlamydial organisms
failed to induce pathologies [21,25], it is assumed that plasmid-
encoded and/or regulated genes play important roles in
chlamydial pathogenesis. The chlamydial plasmid encodes 8 of
its own genes and regulates 22 genes encoded in the genome.
Among the 22 plasmid-regulated gene products, 7 C. trachomatis
proteins were significantly recognized by C. trachomatis-infected
women [26]. We compared the protection efficacy of the 7
antigens using the corresponding C. muridarum orthologs in mice
and found that chlamydial GlgP-immunized mice developed the
most pronounced protective immunity against C. muridarum
intravaginal infection with a significant reduction in vaginal
shedding of live organisms on day 14 after infection. The severity
of oviduct hydrosalpinx was significantly reduced in GlgP-
immunized mice although the overall incidence of hydrosalpinx
Protection Induced by a Glycogen Phosphorylase
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mice. Since the severity of hydrosalpinx can reflect the duration of
tubal blockage and contribute to clinical complications such as
infertility, reducing the severity of hydrosalpinx through vaccina-
tion is medically relevant.
The protective immunity induced by chlamydial GlgP is
somewhat unexpected given the high level of amino acid sequence
homology between chlamydal and host GlgPs. Among the 7
antigens tested, 3 are hypothetical proteins with no significant
homology with any mammalian proteins. Yet, these antigens failed
to induce significant protective immunity. Nevertheless, chlamyd-
ial antigens with amino acid sequence homology with their
counterparts in mammalian hosts have been shown to be
immunodominantly recognized by the mammalian hosts [26,28],
suggesting that the orthologous chlamydial antigens can be
immunogenic in mammalian hosts. Interestingly, antibodies from
the chlamydial GlgP-immunized mice failed to recognize any
GlgPs in mouse tissues, demonstrating that in response to
chlamydial GlgP immunization, the inbred mice selectively
produced antibodies against the variable regions of GlgP and
maintained tolerance to the conserved epitopes. However, it will
be very difficult to predict whether similar tolerance can be
maintained after the repeated injections are applied to outbred
humans during human vaccination. Thus, caution needs to be
taken when considering chlamydial GlgP as a vaccine antigen for
humans.
The GlgP-induced partial protection correlated with GlgP-
specific antibody and Th1-dominant cellular responses. Although
these correlative observations cannot tell us exactly which immune
responses are required for the GlgP-induced protection, evidence
accumulated in the past half century has demonstrated that a Th1-
dominant CD4+ T cell response is essential for controlling
chlamydial urogenital infection [6,15]. Thus, we can reasonably
assume that a GlgP-specific Th1-dominant cellular response may
play a critical role in GlgP-induced protective immunity, which
means that GlgP has to be processed and GlgP-derived epitopes
must be presented by both antigen presentation cells such as
dendritic cells during immunization (for priming naı ¨ve T cells into
Figure 1. Evaluation of 7 plasmid-regulated antigens for inducing protective immunity against C. muridaum intravaginal infection.
(A) Groups of female Balb/c mice with 5/each were immunized intramuscularly with three doses of corresponding antigens plus adjuvant (CpG+IFA)
as indicated in the figure. One month following the final immunization, mice were challenged intravaginally with 2610
4 IFUs of C. muridarum
organisms. Vaginal swabs were taken weekly as indicated along the x-axis for measuring the number of live organisms (IFUs). The IFUs from each
swab was converted into Log10, and the log10 IFUs were used to calculate mean and standard deviation for each mouse group as displayed along
the y-axis. The log10 IFUs were compared between 9 groups of mice at each time point using ANOVA test, followed by a two-tailed Student’s t-test
for comparing between the GST control group and a test antigen group. ** indicates p,0.01 while *, p,0.05. Although three antigen groups
(TC0075, TC0419 & TC0519 or GlgP) displayed significant reduction in live organism shedding, only the GlgP-immunized group maintains a statistic
difference after correcting multiple group comparison. (B) Number of mice with detectable infectious units (IFUs) from each group and at each time
point was listed. The rates of IFU positivity were compared between the GST control and a test group using the Fisher’s exact test. * indicates p,0.05.
Three of the 5 mice immunized with GlgP cleared infection on day 14 post infection.
doi:10.1371/journal.pone.0032997.g001
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intravaginal infection (for T cell recognition of target cells). Since
GlgP is localized within the chlamydial inclusion and most likely
associated with the organisms (Fig. 4A & B of current study), it
would be difficult for the infected cells to access to GlgP from live
organism-laden inclusions. Most likely, the newly infected cells
may take up and process GlgP from dead organisms released from
the burst of previously infected cells. This is possible since
chlamydial inhibition of phagolysosomal fusion is only restricted to
the live organism-laden inclusions/vacuoles [29]. In addition,
presentation of chlamydial GlgP by nearby uninfected epithelial
cells and macrophages may also provide ligands for recognition by
GlgP-specific CD4+ T cells. These T cell recognitions can lead to
a robust production of IFN-gamma and activation of other
immune effector mechanisms at the site of infection or the site
where the infection spreading occurs. IFN-g produced at high
concentrations at the site of infection may significantly inhibit
chlamydial replication and effectively block spreading. The
dependence of GlgP-induced protection on the processing of
GlgP released from already infected cells may partially explain the
result that a significant reduction in live organism shedding in the
GlgP-immunized group occurred only 14 days after infection but
not earlier as in the live organism-immunized group. An earlier
protection may be offered via T cells primed by the antigens that
can be processed and presented by target cells upon an initial
infection. In addition, antibody responses to organism surface-
exposed epitopes may be more robust in reducing the initial
infection. Since the GlgP-immunized mice produced antibodies
that were able to recognize whole EBs in an ELISA, anti-GlgP
antibodies may also play an important role in GlgP-induced
protective immunity. However, it is not clear at this moment
whether GlgP is exposed on live infectious EBs. In any case,
defining the precise molecular and cellular mechanisms of GlgP-
induced protective immunity needs further investigations. Regard-
less of the precise mechanisms involved, the current study has
presented convincing evidence for a proof of concept that
intramuscular immunization with purified chlamydial proteins
can be used to identify vaccine candidate antigens for preventing
C. trachomatis infection and diseases. Efforts are underway to screen
other immunodominant antigens for inducing protective immunity
using the C. muridarum intravaginal infection model. Once
additional protective antigens are identified, more definitive
approaches will be used for comparing their protective mecha-
nisms. Given the complex chlamydial organism structures and
Figure 2. Effect of immunization on genital tract pathologies induced by intravaginal chlamydial infection. The 9 groups of mice
described in Fig. 1 legend were sacrificed for evaluating pathologies of the mouse genital tract tissues. (A) The genital tract gross appearance images
from all 9 groups of mice were presented with each group marked with the name of the corresponding antigens used to immunize the groups. The
entire genital tract from vagina to ovary was displayed from left to right (left panels) and the oviduct and ovary regions were amplified (right panels).
Each oviduct was scored for hydrosalpinx severity under naked eye and a numerical score was assigned for each oviduct as shown in the
corresponding images. The scoring criteria were described in the method section. (B) The number of mice with unilateral or bilateral hydrosalpinx
from each group was summarized. Note that 4 of 5 mice in GST while only 1 of 5 in EB-immunized groups developed hydrosalpinx. (C) The
hydrosalpinx severity scores from each group of mice (indicated along the x-axis) were displayed along the Y-axis. Note that both the EB- and GlgP-
immunized groups developed significantly reduced oviduct pathologies. The hydrosalpinx severity scores were compared between different groups
using ANOVA followed by the two-tailed Student t test. * indicates p,0.05.
doi:10.1371/journal.pone.0032997.g002
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combinations of various antigens with each able to induce unique
effector mechanisms to simultaneously attack multiple stages of the
infection processes may be necessary to achieve a full protection
against chlamydial infection and chlamydial diseases.
Materials and Methods
Ethics Statement
The studies described in the manuscript do not involve human subjects or
non-human primates, thus no institutional review board approval is required.
The use of mice in the manuscript was approved by the University of Texas
Health Science Center at San Antonio Animal Use Protocol Committee. The
protocol number is 09053, which has been evaluated annually. The current
version is valid till April 1 2012.
1. Chlamydial organisms and chlamydial infection in cell
culture
C. muridarum Nigg strain (also called MoPn) organisms were
grown, purified and titrated as described previously [20]. Aliquots
of the organisms were stored at 280uC till use. HeLa cells (ATCC,
Manassas, VA 20108) were maintained in DMEM (GIBCO BRL,
Rockville, MD) with 10% fetal calf serum (FCS; GIBCO BRL) at
37uC in an incubator supplied with 5% CO2. To prepare
chlamydial infection samples for various assays, HeLa cells grown
in tissue culture flasks or on glass coverslips in 24 well plates were
pretreated with DMEM containing 30 mg/ml of DEAE-Dextran
(Sigma, St Luis, MO) for 10 min. After the DEAE-Dextran
solution was removed, chlamydial organisms diluted in DMEM
were added to the monolayers and allowed to attach to the cell
monolayers for 2 h at 37uC. The infected cells were continuously
cultured in DMEM with 10% FCS and 2 mg/ml of cycloheximide
(Sigma) and processed at various time points after infection as
indicated in individual experiments. The infectious dose was pre-
titrated and an infection rate of *50% or less was applied to
samples for immunofluorescence assays or 90% or higher for
Western blot assays or making cell lysates.
2. Prokaryotic expression of chlamydial fusion proteins
and protein purification
Seven ORFs (open reading frames) from C. muridarum genome
were used for the current study: TC0075, TC0285, TC0419 (all
three are hypothetical proteins), TC0181 (glycogen synthase or
GlgA), TC0257 (glycogen branching enzyme or GlgB), TC0519
(glycogen phosphorylase, GlgP) & TC0156 (1-acyl-sn-glycerol-3-
phosphate acyltransferase or AGPAT; (http://www.ncbi.nlm.nih.
gov/sites/entrez). These 7 ORFs are among the 22 chromosomal
genes transcriptionally regulated by the cryptic plasmid [24] and
their counterparts in C. trachomatis were significantly recognized by
C. trachomatis-infected women while the remaining 15 were not. The
7 ORFs were cloned into pGEX vectors (Amersham Pharmacia
Biotech, Inc., Piscataway, NJ) and expressed as fusion proteins with
glutathione-s-transferase (GST) fused to the N-terminus. Expression
of the fusion proteins was induced with isopropyl-beta-D-thioga-
lactoside (IPTG; Invitrogen, Carlsbad, CA) and the fusion proteins
were extracted by lysing the bacteria via sonication in a Triton-
X100 lysis buffer (1% Triton-X100, 1 mM PMSF, 75 units/ml of
aprotinin, 20 mM leupeptin and 1.6 mM pepstatin). After a high-
speed centrifugation to remove debris, the fusion protein-containing
supernatants were purified using glutathione-conjugated agarose
beads (Pharmacia). While some of the bead-bound fusion proteins
were used to deplete antigen-specific antibodies from antiserum
samples, others were further used to purify soluble proteins by
cleavage (for TC0075, TC0156 or AGPAT, TC0181 or GlgA,
TC0257, TC0285 & TC0519 or GlgP) with a precision protease
(Pharmacia) or by elution (TC0419) with reduced glutathione
(Sigma). The cleaved or eluted chlamydial proteins were concen-
trated viacentricon (Millipore,Billerica, MA)and used to immunize
mice for antibody production or evaluating protective immunity as
described previously [27,30].
3. Mouse immunization and urogenital tract infection
For the initial screening experiment, female Balb/c mice were
purchased at the age of 3 to 4 weeks old from Charles River
Figure 3. Enhanced resolution of C. muridarum genital tract
infection by GlgP immunization. GlgP along with two control
groups (GST as negative and EB as positive controls) of mice
(15,17mice/group) were immunized and infected as described in
Fig. 1 legend. (A) Both the EB- and GlgP-immunized groups displayed
significantly reduced levels of live organism shedding on day 14
postinfection and 9 of 15 mice from the EB-immunized group cleared
infection on this day. (B) The incidence of hydrosalpinx from the 3
groups of mice was summarized. (C) The hydrosalpinx scores from each
group were displayed along the Y-axis. ** indicates p,0.01 while * for
p,0.05. The quantitative IFU and semi-quantitative hydrosalpinx score
data were analyzed with Student t test while number of mice with
positive IFUs or with hydrosalpinx were analyzed with Fisher’s Exact
Test.
doi:10.1371/journal.pone.0032997.g003
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groups with 5 in each group. All mice were immunized
intramuscularly (i.m.) for a total of 3 times on day 0, day 20 and
day 30 respectively. A total of 30 mg protein antigen or 10
6 IFUs of
C. muridarum (or MoPn) EBs plus 10 mg of CpG in 50 ml PBS
emulsified in 50 ml of IFA (incomplete Freund’s Adjuvant, Sigma-
Aldrich, St. Luis, MO) was given to each mouse at each time. The
first group was given GST protein as negative and the second
group with EBs as positive control. The remaining 7 groups were
each immunized with one of the 7 test antigens. The CpG with a
sequence of 59-TCC.ATG.ACG.TTC.CTG.ACG.TT-39 (all nu-
cleotides are phosphorothioate-modified at the 39 internucleotide
linkage) was used (Integrated DNA Technologies, IDT, Coralville,
IA). We used the CpG-IFA as adjuvant for the intramuscular
injection because it has been previously shown to induce Th1
dominant immune responses. Thirty days after the third
immunization, each mouse was inoculated intravaginally with
2610
4 IFUs of live C. muridarum organisms in 20 ml of SPG. Five
days prior to infection, each mouse was injected with 2.5 mg
Depo-provera (Pharmacia Upjohn, Kalamazoo, MI) subcutane-
ously. One day before the infection, all mice were bled from the
tail for monitoring antibody responses. In some experiments, mice
Figure 4. Induction of C. muridarum-specific immune responses with GlgP immunization. Three groups of mice with 5 in each group
immunized with GST, C. muridarum (or MoPn) EB or GlgP as described in Fig. 1 legend were sacrificed prior to challenge infection for collecting blood
and splenocytes. (A) The antisera after pooling from each group were used to detect the endogenous C. muridarum antigens in the infected cells
using an immunofluorescence assay. The mouse antibody binding (red) was visualized with a goat anti-mouse Cy3 conjugate (red) and co-labeled
with a rabbit anti-chlamydial organism antibody visualized with a goat anti-rabbit Cy2 conjugate (green) and a DNA dye (blue). To confirm the
staining specificity, the antisera from GlgP- (panels b, d & f) and EB (panels c, e & g)-immunized groups were pre-absorbed with either GST-GlgP
(panels d & e) or C. muridarum-infected cell lysates (f & g). The pooled anti-GlgP antisera were no longer able to label any endogenous antigens after
pre-absorption with either GST-GlgP or C. muridarum-HeLa lysates. However, the binding to endogenous antigens by the pooled anti-EB antiserum
was only blocked by C. muridarum-HeLa lysates. (B) Individual antisera from the 3 groups of mice, after serial dilution, were reacted with purified EBs
coated onto ELISA plates. Antisera from the GlgP-immunized mice significantly recognized the whole organisms although with much lower titers
comparing to the EB-immunized mice. (C) The reactivity of individual antisera from EB (1:800 dilution) or GlgP (1:400) -immunized mice with the
whole organisms coated onto the ELISA plates was also probed with goat anti-mouse Ig isotype-specific secondary antibodies. Both EB- and GlgP-
immunized mice preferentially produced higher levels of IgG2a, indicating the dominance of Th1 cytokines in these mice. ** indicates p,0.01.
doi:10.1371/journal.pone.0032997.g004
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cellular responses. The GlgP immunization experiment was
repeated several times with a total of 15 to 17 mice per group.
4. Monitoring mouse vaginal live chlamydial organism
shedding and evaluating upper genital tract pathologies
To monitor live organism shedding, vaginal swabs were
collected weekly for 4 weeks after intravaginal infection. Each
swab was soaked in 0.5 ml of SPG, and after vortexing, the
chlamydial organisms released into the supernatants were titrated
on HeLa cell monolayers in duplicates as described previously
[19,20,27]. Briefly, serially diluted swab samples were inoculated
onto HeLa cell monolayers grown on coverslips in 24 well plates.
After incubation for 24 hours in the presence of 2 mg/ml
cycloheximide, the cultures were processed for immunofluores-
cence assay as described below. The inclusions were counted
under a fluorescence microscope. Five random fields were counted
per coverslip. The total number of IFUs per swab was calculated
based on the number of IFUs per field, number of fields per
coverslip, dilution factors and inoculation and total sample
volumes. An average was taken from the serially diluted and
duplicate samples for any given swab. The calculated total number
of IFUs/swab was converted into log10 and the log10 IFUs were
used to calculate means and standard deviation for each group at
each time point. Mice were sacrificed 60 days after infection and
the mouse urogenital tract tissues were isolated for gross pathology
evaluation as described previously [19,20]. Both incidence and
severity of hydrosalpinx were recorded for each mouse and
compared between different groups. The severity of hydrosalpinx
was scored based on the following criteria: No hydrosalpinx is
assigned a score of zero (0); Hydrosalpinx is only visible after
amplification (1); Hydrosalpinx is clearly visible with naked eye but
the size is smaller than that of ovary (2); The size of hydrosalpinx is
similar to that of ovary (3); If larger than ovary (4). Apparently, the
hydrosalpinx severity (scored based on the size of the affected
oviduct) largely reflects the amounts of fluids accumulated in the
oviduct. The fluid accumulation may be impacted by both the
duration of the oviduct blockage and the extent of the
inflammatory responses in the oviduct. Regardless how the fluids
are accumulated, the severity of hydrosalpinx has clinical
significance. Numerous clinical studies have shown that women
with more severe tubal damage or larger hydrosalpinges have
statistically significant lower rates of pregnancy and live birth
following in vitro fertilization (IVF) and surgical treatment of
severe hydrosalpinages prior to IVF can significantly increase the
live birth rate [31,32,33,34]. Thus, scoring the hydrosalpinx
severity is a medically relevant measurement.
5. Immunofluorescence assay
HeLa cells grown on glass coverslips in 24 well plates with or
without chlamydial organisms were fixed with 2% paraformalde-
hyde for 30 min, followed by permeabilization with 2% saponin
(Sigma) for an additional 1 h. After washing and blocking, the cell
samples were labeled with Hoechst (blue, Sigma) for visualizing
DNA and a rabbit anti-chlamydial chaperon cofactor antibody
(unpublished data) plus a goat anti-rabbit IgG conjugated with
Cy2 (green; Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) for visualizing chlamydial inclusions. In some
experiments, the monolayers were co-stained with mouse anti-
chlamydial protein antibodies plus a goat anti-mouse IgG
conjugated with Cy3 (red; Jackson ImmunoResearch Laborato-
ries). The immuno-labeled cell samples were quantitated as
described above and used for image analysis and acquisition with
Figure 5. Detection of a Th1-dominant cellular response in
GlgP-immunized mice. Splenocytes harvested from EB (open bar) or
GlgP (hatched bar) -immunized mice as described in Fig. 4 legend were
in vitro re-stimulated with UV-inactivated Chlamydia muridarum EB
organisms at 1610
6 IFUs per well, 10 mg/ml GlgP or medium alone
(none) as indicated at the bottom of the figure. Three days after the
stimulation, the culture supernatants were collected for IFNg and IL-5
detection and the results were expressed as pg or ng/ml as displayed
along the Y-axis (mean 6 SD). Note that both EB and GlgP-immunized
mice produced much higher concentrations of IFNg than IL-5,
indicating a Th1 dominant cellular response in theses mice.
doi:10.1371/journal.pone.0032997.g005
Figure 6. Minimal cross-reactivity of chlamydial GlgP-induced
mouse antibodies with mouse tissue GlgP molecules. C.
muridarum-infected HeLa lysate (lane 1) or extracts from mouse liver
(lanes 2–4), muscle (5–7) and brain (8–10) were resolved in a SDS
polyacrylamide gel and the protein bands were blotted onto
nitrocellulose membrane for Western blot detection with an rabbit
anti-mouse GlgP (panel a) or the pooled mouse anti-chlamydial GlgP
(b). Note that the mouse anti-chlamydial GlgP antibodies preferentially
recognized chlamydial GlgP without any significant cross-reactivity with
mouse tissue GlgP.
doi:10.1371/journal.pone.0032997.g006
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multiple filter sets (Olympus, Melville, NY) as described previously
[35,36,37,38]. All microscopic images were processed using the
Adobe Photoshop program (Adobe Systems, San Jose, CA).
6. Enzyme-linked immunosorbent assay (ELISA)
The cytokines in the supernatants of the in vitro stimulated
lymphocyte cultures were measured using standard cytokine
ELISA kits (mouse IFNg kit, cat# DY485 & IL-5 (cat# DY405,
both from R&D Systems, Inc., Minneapolis, MN) as instructed by
the manufacturer and described previously [19,39]. Briefly,
splenocytes were harvested from immunized mice prior to MoPn
infection and stimulated in vitro with UV-inactivated MoPn EBs,
chlamydial GlgP or medium alone for 3 days. The culture
supernatants were collected for cytokine measurements using 96
well ELISA microplates precoated with the corresponding capture
antibodies. The capture antibody-bound cytokines were detected
with biotin-conjugated antibodies and horseradish peroxidase
(HRP)-conjugated Avidin. The cytokine concentrations were
calculated based on absorbance values, cytokine standards and
sample dilution factors and expressed as ng or pg per ml.
7. Western blot assay
The Western blot assay was carried out as described elsewhere
[40,41]. Briefly, either the C. muridarum GlgP or mouse tissue
samples were solubilized in 2% SDS sample buffer and loaded to a
SDS–polyacrylamide gel. After electrophoresis, the resolved
protein bands were transferred to nitrocellulose membranes for
blotting with primary antibodies, including the mouse pAb against
C.muridarum GlgP or a rabbit anti-mouse liver GlgP antibody
(Rabbit pAb against liver glycogen phosphorylase, cat#15851-1-
AP, ProteinTech Group, Chicago, IL) and the mouse pAb against
C.muridarum TC0519. The primary antibody bindings were probed
with an HRP (horse radish peroxidase)-conjugated goat anti-
mouse or rabbit secondary antibodies and visualized with an
enhanced chemiluminescence (ECL) kit (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA). The various tissue samples harvested
from mouse brain, liver or muscle were homogenized in ice-cold
buffer containing 50 mM HEPES (pH 7.6), 150 mM sodium
chloride, 20 mM sodium pyrophosphate, 20 mM beta-glycero-
phosphate, 10 mM sodium fluoride, 2 mM sodium orthovana-
date, 2 mM EDTA, 1.0% Igepal (a nonionic, nondenaturing
detergent), 10% glycerol, 2 mM phenylmethylsulfonyl fluoride,
1 mM magnesium chloride, 1 mM calcium chloride, 10 mg/ml
leupeptin, and 10 ı `g/ml aprotinin. Tissue homogenates were
centrifuged and the supernatants were resolved in SDS-polyacryl-
amide gel and blotted onto nitrocellulose membrane for antibody
detection.
8. Statistical analysis
ANOVA test (http://www.physics.csbsju.edu/stats/anova.
html) was performed to analyze data from multiple groups and a
two-tailed Student’s t-test (Microsoft Excel) to compare the means
between two groups. A Fisher’s Exact test was used for comparing
the incidences between two groups.
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